Uni-Bio和Kexing伙伴在全球范围扩大骨质疏松症药物Bogutai,目标是一个1.5B的市场。 Uni-Bio and Kexing partner to expand osteoporosis drug Bogutai® globally, targeting a $1.5B market.

Uni-Bio科学集团和Kexing生物药业合作在全球扩大骨质疏松症治疗 Bogutai。 Uni-Bio Science Group and Kexing Biopharm have partnered to expand the osteoporosis treatment Bogutai® globally. Kexing生物制药公司获得了在六个国家出售Bogutai的独家专有权利,目标是一个价值近15亿美元的市场,拥有1 000多万病人。 Kexing Biopharm gains exclusive rights to sell Bogutai® in six countries, targeting a market valued at nearly $1.5 billion with over 10 million patients. 该伙伴关系将处理骨骼损失和骨骼形成的治疗结合起来,旨在满足全球对骨质疏松症护理日益增长的需求。 The partnership combines treatments to address bone loss and formation, aiming to meet growing global demand for osteoporosis care.